1. Israel Stocks

  2. •

    Health technology

  3. •

    Medical specialties
BioView Ltd.

BioView Ltd.

TTASE:BIOV
5,001.00
ILA
-325.00
(-6.10%)
4.88BMarket Cap
BioView Ltd.
TASE:BIOV
(Tel Aviv Stock Exchange)

Recent

price

5,001.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
ILS
199.22
196.77
194.93
171.57
223.93
251.88
239.62
198.91
178.95
252.17
184.63
218.32
215.24
256.76
193.18
14.69
- -
Revenue per Share
41.2
49.45
10.79
-8.02
15.61
29.66
31.94
-8.97
-13.12
17.79
6.29
15.63
4.34
2.83
-23.7
-11.3
- -
Basic EPS, GAAP
- -
22.9
12.88
-23.24
23.44
32.47
25.97
-1.06
-10.65
16.12
3.54
18.52
3.77
-0.89
-23.65
-2.29
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
19.97
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
113.66
124.85
116.5
134.28
166.1
198.15
167.96
160.24
175.46
179.37
194.33
203.31
203.06
177.21
67.74
212.24
Book Value per Share
- -
106.96
118.9
111.61
130.45
162.6
194.68
165.11
159.45
175.46
179.37
194.33
203.31
203.06
177.21
67.74
212.24
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
Basic Weighted Avg Shares
25
26
26
23
30
35
33
28
25
36
26
31
29
35
26
20
- -
Sales/Revenue/Turnover
16.76
13.78
7.52
-3.22
4.88
10.8
13.98
-1.02
-10.41
12.18
8.36
11.64
0.35
1.81
-11.58
-39.15
- -
Operating Margin (%)
- -
- -
- -
1
- -
- -
- -
- -
1
1
1
1
1
2
2
2
- -
Depreciation Expense
5
7
1
-1
2
4
4
-1
-2
3
1
2
1
- -
-3
-15
- -
Net Income, GAAP
- -
- -
13.81
- -
5.89
- -
4.79
- -
- -
25.03
22.52
18.6
32.91
51.94
- -
- -
- -
Effective Tax Rate (%)
20.68
25.13
5.54
-4.67
6.97
11.77
13.33
-4.51
-7.33
7.06
3.41
7.16
2.01
1.1
-12.27
-76.93
- -
Profit Margin (%)
- -
14
15
12
14
18
22
17
16
18
18
20
21
20
15
8
21
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
4
3
2
- -
1
2
LT Debt
- -
15
17
16
18
23
28
23
23
25
25
27
28
27
23
9
29
Total Equity
- -
- -
9.22
- -
13.97
- -
17.83
- -
- -
10.13
3.45
8.24
2.4
1.16
- -
- -
- -
Return on Invested Capital (%)
- -
- -
9.04
- -
12.46
- -
17.54
- -
- -
10.25
3.41
8.14
2.33
1.69
- -
- -
- -
Return on Capital (%)
- -
- -
9.04
-6.65
12.46
19.75
17.54
-4.9
-8.03
10.59
3.53
8.36
2.12
1.38
-12.53
-94.76
- -
Return on Common Equity (%)

Capital Structure

ILS

•

in mil. unless spec.
Sep'22
Dec'22
Jun'23
ST Debt
1
1
2
LT Borrowings
- -
- -
- -
LT Finance Leases
3
3
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
54
51
49

Working Capital

ILS

•

in mil. unless spec.
Sep'22
Dec'22
Jun'23
Total Current Assets
30
31
31
Cash, Cash Equivalents & STI
19
19
18
Accounts Receivable, Net
6
5
7
Inventories
5
5
5
Total Current Liabilities
8
10
10
Payables & Accruals
- -
- -
- -
ST Debt
1
1
2
Deferred Revenue
- -
- -
- -

Growth Rates

ILS

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-5.37%
-13.18%
-58.97%
Free Cash Flow
317.42%
542.12%
-0.99%
Net Income, GAAP
-86.79%
-99.14%
387.04%
Sales/Revenue/Turnover
-3.12%
-3.24%
-22.32%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

ILS

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
35
2024
- -
- -
26
2025
- -
- -
20

Semi-annual Earnings Per Share

ILS

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
2.83
2024
- -
- -
-23.7
2025
- -
- -
-11.3

Semi-annual Dividends Per Share

ILS

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Bio-View Ltd (BIOV.TA) develops, manufactures and markets automated cell imaging and analysis solutions for cytology, cytogenetic and pathology applications in clinical and research laboratories worldwide. Founded in 1998 and headquartered in Rehovot, Israel, the company offers a comprehensive suite of products including Accord, a semi-automated fluorescent imaging workbench; Accord Plus, an automatic system for scanning, analyzing and sorting FISH and karyotype samples; Allegro Plus, a fluorescent imaging system detecting chromosomal aberrations such as amplifications, translocations, inversions and deletions; DUET-3, a multi-application automated imaging system; Encore, an automated barcode reader for batch scanning; DeNovo, a scanning system for circulating tumor cell detection, analysis and characterization from peripheral blood; Solo Workstation and Solo Touch Workstation for offline review and analysis; and SoloWeb, a web-based platform for analysis, reporting and consulting. Bio-View operates primarily in the medical devices sector, targeting cancer diagnostics and genetic testing markets with installations across Israel and international regions. In recent developments, the company maintains a strategic partnership with ANGLE plc to co-develop a liquid biopsy assay for HER2 detection in circulating tumor cells for breast cancer, with promising initial results presented at the AACR International Liquid Biopsy Conference in December 2024.